Increased risk of nonrelapse mortality post T‐cell‐replete haploidentical stem cell transplantation in patients with recurrence of acute graft‐versus‐host disease. Issue 4 (17th April 2022)

• Record Type: Journal Article
• Authors: Peng, Bo; Dou, Liping; Yang, Jingjing; Wang, Lili; Li, Fei; Gao, Xiaoning; Wang, Shuhong; Jin, Xiangshu; Wang, Lu; Jia, Mingyu; Wang, Shenyu; Li, Yan; Liu, Daihong
• Is Part Of: Hematological oncology. Volume 40:Issue 4(2022)
• Page Start: 743
• Page End: 751
• Publication Date: 2022-04-17
• Subjects: acute graft‐versus‐host‐disease -- haploidentical -- hematopoietic cell transplantation -- nonrelapse mortality -- recurrence; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.2999
• Languages: English
• ISSNs: 0278-0232

Abstract

Abstract: Acute graft‐versus‐host disease (aGVHD) causes significant morbidity and mortality. While most studies focus on classic or late aGVHD, some patients with previous aGVHD achieve complete remission and later develop another episode of aGVHD. Data on recurrence of aGVHD (RaGVHD) are lacking. This study aimed to identify the incidence, risk factors, and impacts of RaGVHD after T‐cell‐replete haploidentical hematopoietic cell transplantation (haplo‐HCT) without posttransplantation cyclophosphamide. We evaluated patients with RaGVHD after haplo‐HCT between 2017 and 2019 and compared their outcomes to those of patients with no aGVHD and those of patients with one episode of de novo aGVHD. Of 199 patients included in the analysis, 45 experienced 50 cases of RaGVHD with a 1‐year cumulative incidence of 19.0% (95% CI: 14.5–24.6). Grade III–IV aGVHD was more common in RaGVHD than in previous aGVHD (22.2% vs. 4.4%, p = 0.01). Female donor to male recipient was strongly associated with RaGVHD (HR: 2.5, p = 0.009). The most common death in patients with RaGVHD was GVHD‐related, which was different from controls who mostly died from relapse ( p = 0.008). RaGVHD was an independent risk factor for chronic GVHD (HR: 2.6, p = 0.006) and nonrelapse mortality (HR: 2.4, p = 0.019) and a significant predictor of lower GVHD relapse‐free survival (HR: 1.9, p = 0.020) and cGVHD relapse‐free survival (HR: 2.1, p = 0.007). In conclusion, clinical manifestations and negative impacts of RaGVHD needs to be recognized independently.